Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 24 for “"CDK4/6"”.
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
… and tumorigenesis. The crucial role of the CDK4/6-Cyclin D pathway has led to the development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of advanced estrogen receptor positive breast cancer. However, three major clinical challenges remain: i) adverse …
-
Simultaneous Targeting of CDK4/6 and BETs is Independent of RB Status in Osteosarcoma
… (MYC, RAD21) and cell cycle regulators (CDKN2A, CDK4/6), pointing to CDK4/6 inhibitors (CDK4/6i), like palbociclib and abemaciclib, as promising therapeutic strategies. However, monotherapy often fails, highlighting the need for effective combination approaches. While functional RB has …
-
Overcoming Resistance to CDK4/6-targeted Therapy Using JAK2/STAT3 Inhibitor in Triple-Negative Breast Cancer
… and metastasis. Cyclin-dependent kinase 4 and 6 (CDK4/6) are major cell cycle regulators that control G1 to S phase transition and aberrant hyperactivation of the CDK4/6 pathway results in uncontrolled cell proliferation. Although three CDK4/6 inhibitors (CDK4/6is) have achieved clinical benefits …
-
Combined Inhibition of Ddr1 and Cdk4/6 Induces Synergistic Effects In Er-Positive, Her2-Negative Breast Cancer With Pik3Ca/Akt1 Mutations
<p><strong>COMBINED INHIBITION OF DDR1 AND CDK4/6 INDUCES SYNERGISTIC EFFECTS IN ER-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH <em>PIK3CA/AKT1</em> MUTATIONS</strong></p> <p>Maryam Shariati, M.S. Advisory Professor: Funda Meric-Bernstam, M.D.</p> <p>Molecular alterations in the phosphatidylinositol …
-
Impact of Cyclin-Dependent Kinase 4 and 6 Inhibitors on Chemotherapy Utilization and Overall Survival in Women with HR+/HER2– Metastatic Breast Cancer in the United States
… the impact of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy class, introduced in 2015, on early chemotherapy utilization in an older population of patients with HR+/HER2– MBC in the United States (US). Methods: Using an interrupted time series design, patients with a confirmed …
-
Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells
… days. In addition to palbociclib, we add another Cdk4/6 inhibitor to the model, abemaciclib, which can induce apoptosis at high concentrations. Then the model can match the effects of abemaciclib treatment at two different doses and also capture the apoptosis effects induced by abemaciclib. After …
-
Prevalence of Pik3ca-Mutations and Response to First-Line Endocrine Therapy in a Population of Bulgarian Patients with HR(+) HER2(–) Metastatic Breast Cancer // Честотата на PIK3CA-мутацията и отговорът към първа линия ендокринна терапия в популацията от български пациентки с HR(+)HER2(-) метастазирал карцином на гърдата
… survival and OS in first-line therapy with ET±CDK4/6 inhibitor in patients with confirmed PIK3CA mutation and those without mutation.
-
Androgen receptor-mediated growth suppression and apoptosis of human prostate epithelial cells
… is dependent on the inhibition of cyclin D-CDK4/6 complexes through transcriptional repression of the CDK4 and CDK6 genes and transcriptional activation of the CDKN1A/p21 gene. Further, AR inhibits cyclin D2 transcription and destabilizes cyclin D1 mRNA in HPr-1AR cells. The decreased …
-
Genome-scale Precision Proteomics Identifies Cancer Signaling Networks and Therapeutic Vulnerabilities
… actionable lesions. Recent success targeting CDK4/6 and MEK in RAS mutant adult cancers led our collaborator Dr. Dyer’s group to test this approach for rhabdomyosarcoma. They achieved synergistic killing of RAS mutant rhabdomyosarcoma tumor cells by combining MEK and CDK4/6 inhibitors in …
-
Role of the cell cycle during human endothelial-to-haematopoietic transition
… the haematopoietic fate. Furthermore, I identify CDK4/6 and CDK1 as key regulators affecting this process. Ultimately, I propose here a direct link between the molecular machineries controlling cell cycle progression and cell fate decision, determining the capability of haemogenic endothelial …
-
Mapping the cell cycle-dependent centrosomal interactome
… cell cycle synchronisation method based on the CDK4/6 inhibitor palbociclib. Differential analysis of the centrosome interactome resulted in the identification of proteins associated with numerous biological processes, including gene expression, DNA/RNA processing, and cell cycle regulation. …
-
Συστηματική ανασκόπηση της αποτελεσματικότητας και της ασφάλειας του Giredestrant στη θεραπεία του καρκίνου του μαστού - Systematic review on the efficacy and safety of Giredestrant for breast cancer therapy
… exemestane + everolimus μετά από πρόοδο υπό CDK4/6-αναστολείς. Τρεις επιπλέον μελέτες φάσης III (lidERA BC, persevERA BC, pionERA BC) βρίσκονται σε εξέλιξη. Το giredestrant ήταν γενικώς καλά ανεκτό, με τις περισσότερες ανεπιθύμητες ενέργειες να είναι βαθμού 1-2. Συμπεράσματα: Το giredestrant …
-
Modulation of the Hippocampal Neurogenic Program by the Circadian Clock Machinery and the small GTPase, Rasd1/ Dexras1
… cell-cycle inhibitors that targets the cyclin D/Cdk4-6 complex, and in turn disruptions in this system result in the abolishment of gating mechanisms. This study uncovers the interrelationship between the cell cycle and the circadian clock and emphasizes the importance of proper rhythmicity for …
-
A SEARCH FOR EPIGENETIC VULNERABILITIES OF AML CELLS PERFORMED BY A CDK INHIBITOR¿BASED CRISPR SCREENING
… of the cell cycle through sub-optimal doses of CDK4/6 inhibitors reprograms the chromatin landscape of fast-cycling AML cells resistant to LSD1 inhibition, rendering them more similar to slow-cycling counterparts that are intrinsically sensitive to LSD1 inhibition. This finding suggested that …
-
SMAD2/3 - FOXH1 regulation during cell cycle progression upon differentiation
… direct cell fate propensity either by activating CDK4/6 activity, which results in blocking SMAD2/3 nuclear entry or by directly binding to developmental genes and co-recruiting epigenetic modifiers. Despite the importance of these interplay, the molecular mechanisms orchestrating transcriptional …
-
Stability, folding and evolution of the tumour suppressor protein p16.
… disruption of structural scaffold, distortion of CDK4/6-binding sites and reduction in thermodynamic stability. The coding sequence of p16 is exceptionally rich in CpG dinucleotides (almost eight times the average mammalian frequency), which may be one of the causes of the genetic instability of …
-
Investigating the role of cell cycle regulators in mesoderm specification
… I have shown that the cell cycle regulators CDK4/6, CDK2, Retinoblastoma phosphorylation and CDK1 are essential for mesoderm subtype formation. Furthermore, I have shown that CDK1 regulates the activity of ERK1/2 signalling, an important pathway for the differentiation process confirming the …
-
Targeting Transcription Factors in Neuroblastoma: Development of Aurora Kinase A/N-Myc Degraders and ID2 Chemical Probes
… developed through chemical modifications of the CDK4/6 inhibitor ribociclib. A series of Aurora-A/N-Myc degraders were subsequently developed using proteolysis targeting chimera (PROTAC) technology. The representative compound, 2.3 (HLB-0532259), potently decreases N-Myc protein levels following …
-
Opportunities and challenges in oncology targeted drug development : an assessment of the use of prevalence and companion diagnostic performance thresholds to guide clinical trial strategies
… of ten "pathway-modifying" cancer drug programs (CDK4/6, MDM2 and P13KP inhibitors) that reflect the biological complexity of future targeted therapies. These interviews provided empirical data as to how biomarkers are being incorporated into current clinical trial decisions. All respondents were …
-
A Compendium of Genetic Drivers for Oesophageal Adenocarcinoma defines Prognostic and Therapeutic Biomarkers for use in the Clinic
… 50% of OACs contained sensitizing events for CDK4 and CDK6 inhibitors, which were highly correlated with clinically relevant sensitivity in a panel of OAC cell lines and organoids. In a smaller panel of OACs we also saw evidence for specificity of BET inhibitor efficacy to MYC amplified OACs, …
Page 1 of 2